Discussion
cognitive aging, ADAS‐cog
BLOOD, OXIDATIVE STRESS, SECONDARY
The main findings of this benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for AD included: (i) 1000 mg of benzoate led to the best outcome, while 750 mg/day also generated similar efficacy to 1000 mg/day (Table In addition to a potential DAAO inhibitor,Blood DAAO levels were found to be related with cognitive aging in both cross‐section and prospective studies.Supporting the oxidative stress theory of AD,Sodium benzoate's oxidative‐stress reduction actitivityFor detailed comparisons, in the previous pilot AD trial,In terms of the safety domain, the current study found that all three doses (500, 750, and 1000 mg/day) of benzoate and placebo had similar performance (Table This study was limited by its moderate sample size, which might have led to underpowered results. Further, regarding multiplicity adjustments, this study had one primary outcome (ADAS‐cog) and two secondary outcomes (CIBIC‐plus and additional cognition composite). If we considered the primary and secondary outcomes separately, it would have been dispensable to correct the 